AUBREY PETERSON: Open Payments
NPI 1023590007 · HUTCHINSON, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$779 in 35 payments from 17 companies in 2025. Trend: 2023 $902 · 2024 $689 · 2025 $779
Food & beverage: $779
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $205 |
| Lilly USA, LLC | 6 | $102 |
| ABBVIE INC. | 4 | $83 |
| Novo Nordisk Inc | 4 | $62 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| Amgen Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $26 |
Products named: AIRSUPRA, VRAYLAR, GEMTESA, FARXIGA, JARDIANCE, Ozempic, GVOKE HYPOPEN, SHINGRIX.
Industry payments across KS — which companies pay providers there.
